Drug Database
CS

CSF-GM (Leucogen)

✓ Approved

LG Chem Ltd. · CSF2RA · 重组蛋白

什么是 CSF-GM?

CSF-GM 是一种重组蛋白,由LG Chem Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Leucogen
公司LG Chem Ltd.
药物类别重组蛋白
分子靶点CSF2RA
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

CSF-GM 作用于 1 个分子靶点:

CSF2RAcolony stimulating factor 2 receptor subunit alpha (CD116, CSF2RX)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

CSF-GM 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Leukaemia✓ Approved
Blood and lymphatic system disordersMyelosuppression✓ Approved

相关研究文献

PubMedMolecular neurodegeneration2026-11-19

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

Pelkmans Wiesje W, Cacciaglia Raffaele R, Kassinopoulos Michalis M, Grau-Rivera Oriol O et al.

Structural brain changes during the earliest asymptomatic stages of Alzheimer's disease (AD) remain poorly understood. Previous research in preclinical AD shows heterogeneous findings, reporting both subtle neuronal loss and paradoxical increases in grey matter (GM) volume. This study applies an extensive cerebrospinal fluid (CSF) biomarker panel to better understand the biological processes underlying longitudinal GM changes in cognitively unimpaired (CU) adults, spanning the amyloid/tau (AT) continuum. We analysed data from 627 CU individuals from three longitudinal cohorts (ALFA+, Wisconsin ADRC, WRAP), with repeated MRI (3.5 ± 0.9 years) and baseline CSF biomarkers from the NeuroToolKit panel (Roche Diagnostics). Using non-negative matrix factorization, we decomposed the CSF biomarker levels into six latent components, reflecting amyloid-β (Aβ) pathology, tau-related pathophysiology with synaptic injury, neuroaxonal injury, microglial reactivity, astrocytic reactivity, and cytokine signalling. We tested associations between component weights and voxel-wise longitudinal GM volume changes using single-component and a joint-all components model. Analyses were performed across the full sample and stratified by AT status. Associations with longitudinal cognitive performance (PACC) were assessed using linear mixed-effects models. The Aβ pathology component was the strongest and most widespread predictor of longitudinal GM atrophy, predominantly in temporal and frontal regions, also when controlling for tau pathophysiology, neuroaxonal injury, or neuroinflammatory components. Higher Aβ pathology scores were also associated with cognitive decline. The component capturing tau-related pathophysiology and synaptic injury initially associated with GM loss but lost significance after accounting for other biomarker components. In contrast, components reflecting microglial reactivity, astrocytic reactivity, and cytokine signalling were associated with longitudinal GM volume increases, with effects varying by AT stage. In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury. While glial and inflammatory processes may contribute to transient GM increases in preclinical AD. A better understanding of these dynamic relationships between structural brain changes and various biological pathways at the earliest stages of AD is crucial to inform the development of interventions before irreversible neurodegeneration occurs.

PMID 43053204
阅读全文 →
PubMedNutrition & metabolism2026-11-19

Associations between gut microbiota-modulating diets and their components and metabolic syndrome.

Chen Bowen B, Xue Erxu E, Liu Shan S, Fang Chenhao C et al.

Diet and gut microbiota alterations are key contributors to metabolic syndrome (MetS). As the Dietary Index for Gut Microbiota (DI-GM) captures diet-microbiome interplay, we examined the associations of DI-GM and its components with MetS. A total of 13,684 participants aged 20 years or older from the National Health and Nutrition Examination Survey 2007-2018 were included. DI-GM scores were calculated based on the mean dietary intake from two 24-h dietary recalls. Survey-weighted logistic regression, restricted cubic splines, and stratified analyses were used to assess associations, nonlinear dose-response patterns, and susceptible subgroups. Furthermore, weighted quantile sum (WQS) regression was employed to evaluate the collective impact of DI-GM components on MetS risk. Higher DI-GM scores were associated with a lower odds of MetS, particularly for the unfavorable gut microbiota component (DI-GM: OR = 0.90, 95% CI: 0.86-0.93; unfavorable component: OR = 0.80, 95% CI: 0.76-0.85). Participants with scores ≥ 6 had markedly lower odds of MetS (OR = 0.63, 95% CI: 0.54-0.74) compared with those scoring 0-3 (P for trend < 0.001). Restricted cubic spline analyses indicated a linear association between DI-GM and MetS. The inverse association was more pronounced among individuals without diabetes (P for interaction < 0.05). Higher DI-GM scores were associated with lower odds of MetS. These findings highlight the potential value of microbiota-focused dietary assessment for informing MetS-related dietary research and prevention strategies.

PMID 43053115
阅读全文 →
PubMedNature aging2026-11-19

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology.

Warmenhoven Noëlle N, Binette Alexa Pichet AP, Collij Lyduine E LE, Janelidze Shorena S et al.

Plasma biomarkers for Alzheimer's disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ42/Aβ40 and p-tau181/Aβ42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic (n = 129), a primary care (n = 220) and a research cohort (n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83-91%) and p-tau217/Aβ42 (83-92%) had comparable accuracies to CSF (88-90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90-97%) remained comparable to CSF (91%) in the clinical cohorts (all Padj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

PMID 43052398
阅读全文 →
PubMedJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2026-11-19

Corrigendum to "Neutropenia and G-CSF use in patients receiving FOLFOX during the COVID-19 pandemic".

PMID 43053620
阅读全文 →
PubMedCritical care (London, England)2026-11-19

CT-based radiomics for interpretable outcome prediction after aneurysmal subarachnoid hemorrhage: a multicenter cohort study.

Wu Yanze Y, Hu Ping P, Yan Tengfeng T, Xiao Yuxin Y et al.

Prognostic assessment after aneurysmal subarachnoid hemorrhage (aSAH) mainly relies on clinical variables and computed tomography (CT) findings, but current models often lack biological interpretability. We developed and validated a clinical-radiomics prognostic model and subsequently performed exploratory cerebrospinal fluid (CSF) proteomic characterization of model-defined risk phenotypes. This multicenter cohort from the PROSAH-MPC registry included 879 patients across four hospitals. Patients from the primary center were split into training (n = 637) and internal validation (n = 160) cohorts, while patients from three other centers formed an external validation cohort (n = 82). Admission CT hemorrhagic lesions were automatically segmented using the validated BrainHemoAI platform, and radiomic features were extracted with PyRadiomics. Clinical, radiomics, and combined clinical-radiomics XGBoost models were developed and interpreted using SHapley Additive exPlanations (SHAP). Risk scores from the clinical-radiomics model were applied to an independent prospective enrichment, gene setCSF​ proteomic cohort to define combined model-based high- and low-risk groups. Gene Ontology (GO)/ Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, gene set enrichment analysis (GSEA), and protein-protein interaction (PPI) analyses were performed. The combined model yielded AUCs of 0.892 and 0.820 in the internal test and external validation cohorts, respectively. Risk reclassification analyses suggested that radiomic features may provide complementary prognostic information. SHAP identified radiomic heterogeneity and key clinical variables as major predictors. Meanwhile, exploratory CSF proteomic analysis identified candidate differentially expressed proteins and associated pathway signals that differed between groups defined by high and low combined clinical-radiomics risk scores. This clinical-radiomics prognostic model enables accurate outcome prediction and provides exploratory biological insight into unfavorable recovery after aSAH, supporting refined risk stratification and potential targeted therapeutic development. PROSAH-MPC. NCT05738083. Registered 16 November 2022 - Retrospectively registered, https://clinicaltrials.gov/study/NCT05738083 .

PMID 43053186
阅读全文 →
PubMedClinical pediatrics2026-11-19

Development and Validation of an Early Clinical Prediction Model for Post-Encephalitic Epilepsy in Children With Viral Encephalitis: A Single-Center Retrospective Cohort Study.

Xu Bin B, Xie Jinyang J, Liu Jianping J

Post-encephalitic epilepsy (PEE) is a serious long-term sequela of pediatric viral encephalitis, yet early risk stratification tools are lacking. In this single-center retrospective cohort study of 206 children with viral encephalitis, 43 (20.87%) developed PEE during follow-up. A multivariable logistic regression model incorporating 4 early clinical predictors-acute seizure count, cerebrospinal fluid (CSF) white blood cell count, consciousness disturbance, and cortical involvement-demonstrated good discrimination and acceptable calibration. Decision curve analysis showed higher net benefit than treat-all and treat-none strategies across threshold probabilities of approximately 0.06 to 0.99. Sensitivity analyses, including false-discovery rate correction, adjustment for follow-up duration, pathogen-stratified analyses, and a time-to-event (Cox) model, did not materially alter the principal findings. This model, built from routinely available variables, showed promise for early identification of children at elevated risk for PEE in internal validation. External validation in independent multicenter cohorts is warranted before clinical implementation.

PMID 43052691
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多CSF-GM